Obesity Clinical Trial
— ROBUSTOfficial title:
Reducing Obesity Using Social Ties (ROBUST): Randomized Control Trial
This trial aims to test the feasibility and acceptability of addressing interpersonal barriers to weight-related behavior change. Specifically, the study will test if, by including up to two friends, family members, or co-workers in a lifestyle intervention for weight loss, the person enrolled in the study loses more weight than someone whose friends, family members, or co-workers were not invited to participate.
Status | Recruiting |
Enrollment | 264 |
Est. completion date | March 2026 |
Est. primary completion date | March 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Index Participant: 1. Black race or Hispanic ethnicity 2. Male or Female 18 years of age or older 3. Calculated BMI > 30kg/m2 from objectively measured height and weight by study staff 4. Access & willingness to use program food intake app via home computer or a smartphone 5. Ability to identify at least one adult social network member who will participate in the study - Social Network Member: 1. Male or Female 18 years of age or older 2. Access to the internet or a smartphone Exclusion Criteria: - Index Participant: 1. Active enrollment in a weight-loss program, use of weight-loss medications, or planning weight-loss surgery 2. Advanced medical illness, dementia, hospitalization, injury, or pregnancy that inhibits regular physical activity 3. Contraindications to exercise based on the Physical Activity Readiness Questionnaire or lack of clearance from a health care provider 4. Unresolved Food insecurity 5. Speaks a language other than English or Spanish - Social Network Member: 1. Speaks a language other than English or Spanish |
Country | Name | City | State |
---|---|---|---|
United States | Weill Cornell Urology | Brooklyn | New York |
United States | Weill Cornell Internal Medicine Associates | New York | New York |
United States | Weill Cornell Primary Care at Lower Manhattan | New York | New York |
United States | Weill Cornell Urology | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Weill Medical College of Cornell University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants who have attended at least 75 percent of the behavioral coaching sessions | End of study (24 weeks) | ||
Primary | Number of intervention participants who have at least one social network member engage in the study | End of Study (24 weeks) | ||
Primary | Number of participants and social network members combined who complete the final study assessment | End of Study (24 Weeks) | ||
Secondary | Change in positive communication and problem solving as measured by the McMaster Family Assessment Device (FAD) Questionnaire | The lowest score on the McMaster Family Assessment Device (FAD) Questionnaire a participant can receive is 60 and the highest score on the McMaster Family Assessment Device (FAD) Questionnaire a participant can receive is 240. Higher scores mean positive family communication and problem solving. | Baseline, End of Study (24 weeks) | |
Secondary | Change in weight related social norms | A 5 point Likert scale that measures unhealthy weight norms. The lowest score is 7 and the highest score is 35. Higher scores mean healthy eating and physical activity weight norms. | Baseline, End of Study (24 weeks) | |
Secondary | Change in median Fitbit wear time in minutes | Total minutes spent in very active intensity during activity | Weekly up to 24 weeks | |
Secondary | Change in total caloric amounts on three-day food record | Participants complete food records at minimum 3 days a week | Weekly up to 24 weeks | |
Secondary | Change in median number of days that the Fitbit is worn | Weekly up to 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |